Dated developments that change what you pay or how you are screened, newest first.
Latest
As of October 15, 2026, this ledger lists 12 dated developments since mid-September that affect people paying cash for GLP-1 care through telehealth, led by a CNN report on eating-disorder screening, FDA warning letters, Medicare Bridge changes and our own monthly price re-read.
Each item links to its primary source and says whether it is confirmed or only reported.
Newest first. "Confirmed" means we read the primary source; "reported" means the item comes from a company release or press report we could not check against a primary page.
· confirmed
CNN reports people with anorexia obtaining GLP-1s through telehealth
CNN published an investigation on October 15 in which clinicians describe a sharp rise in patients with anorexia using GLP-1 medications, many obtained online with little screening. One patient told CNN he got a GLP-1 from Hims & Hers after lying about his weight and also bought from Ro, Good Life Meds, MEDVi and Priority Meds. Hims & Hers told CNN that eating-disorder screening is mandatory in its prescribing process.
What it means if you pay cash: Expect more scrutiny of form-only intake. Before you pay, ask a program how it checks weight and whether a clinician speaks with you; our screening guide lists what each program states. Read more
Medicare Open Enrollment opens; Lilly sets October 29 for third-quarter results
Medicare Open Enrollment runs from October 15 to December 7, 2026, with plan changes taking effect January 1. Separately, Eli Lilly said it will report third-quarter results on October 29, the first chance to see whether its self-pay Zepbound and Foundayo prices change for 2027.
What it means if you pay cash: The Medicare GLP-1 Bridge needs Part D or Medicare Advantage drug coverage but no particular plan. Cash-pay Zepbound prices are unchanged until Lilly says otherwise.
October price re-read: what changed among the programs we review
Our October 15 re-read of the programs this site reviews found Sunlight advertising a fall promotion ($157 tirzepatide, $88 semaglutide, against a 'starting at $179' card) and no longer showing a money-back weight-loss guarantee; Direct Meds now lists tirzepatide injections at $399 a month and has dropped the $224.10 sublingual figure we showed in July; TMates charges $297 a month or $167 a month on a $1,999 prepaid year; Fridays' lowest prices ($198 tirzepatide, $99 semaglutide) need a promo code and a 12-month subscription; MEDVi's semaglutide first month is $149 to $179, with refills at $299. BetterMe Rx, Remedy Meds and Noom Med print no molecule-specific compounded price, and Ro blocked our reader.
What it means if you pay cash: Compare the year cost, not the first month: several programs now bill every four weeks (13 charges a year) or require a prepaid year for their lowest figure. Read more
· reported
Walmart adds no-cost Ozempic and Mounjaro for employees with diabetes, not for weight loss
CNBC reported that Walmart will cover more than 250 prescriptions at no cost to employees in 2027, including Ozempic and Mounjaro for type 2 diabetes after prior authorization. Walmart still does not cover GLP-1 medications prescribed for weight loss.
What it means if you pay cash: Large employers are still leaving weight-loss GLP-1s out, so most people using them for weight alone keep paying cash.
Ozari Health announces two compounded GLP-1 plans in a paid release
A paid GlobeNewswire release describes Ozari One (compounded semaglutide with B12 at $86 a month and tirzepatide with B12 at $125 a month, billed every three months, not in California) and Ozari Select (monthly to annual plans from $175 to $99 for semaglutide and $235 to $140 for tirzepatide). We have not read Ozari's own pricing pages, so these figures are not in our index.
What it means if you pay cash: Press-release prices are a starting point, not a verified price. Check the plan length and billing before comparing.
FDA posts warning letters to two websites selling unapproved semaglutide
FDA posted warning letters 737806 (onlinegenericmedicine.com, dated September 23) and 737810 (cheapmedicineshop.com, dated September 24). Both sites sold injectable semaglutide under other product names ("Semanat" and "Semanext") that FDA calls unapproved and misbranded.
What it means if you pay cash: There is no approved generic semaglutide in the U.S. A "generic Ozempic" offer from an online shop is a red flag, not a bargain. Read more
FDA updates its consumer page on unapproved GLP-1 drugs
FDA's page "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss" now shows content current as of October 1. It lists telehealth red flags, says compounded multi-dose GLP-1 vials should be discarded 28 days after first use, warns against semaglutide salt forms and states that retatrutide and cagrilintide cannot be used in compounding under federal law. It counts 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of May 31, 2026.
What it means if you pay cash: If your program ships multi-dose vials, ask how long each vial lasts at your dose so you are not asked to use one past 28 days.
Rhode Island Medicaid stops covering GLP-1s prescribed only for weight loss
Under Rhode Island's fiscal 2027 budget, Medicaid stopped covering Foundayo, Saxenda, Wegovy and Zepbound when prescribed solely for weight loss, effective October 1, 2026. Coverage continues for type 2 diabetes and other approved uses such as cardiovascular risk reduction.
What it means if you pay cash: Affected members must switch to self-pay options (LillyDirect, NovoCare or telehealth) or stop treatment; talk to your prescriber before stopping.
CMS: Medicare GLP-1 Bridge runs through 2027; BALANCE will not launch in Medicare in 2027
CMS's BALANCE model page, updated September 29, says the Medicare GLP-1 Bridge has been extended through December 31, 2027 and that the BALANCE model will not launch in Medicare in 2027. The Bridge gives eligible Part D enrollees a $50 copay for covered weight-loss GLP-1s outside the normal Part D benefit.
What it means if you pay cash: If you have Medicare and qualify, $50 a month for a brand GLP-1 is less than almost every cash-pay compounded price we track, and it buys the FDA-approved product.
Two men charged over counterfeit Ozempic sold in the U.S.
FDA announced that federal prosecutors in the Middle District of Florida charged two Indian nationals with conspiracy and smuggling. Court documents allege they distributed counterfeit Ozempic sourced from China between July 2023 and April 2024. The charges are allegations.
What it means if you pay cash: Buy brand GLP-1s only through licensed pharmacies, LillyDirect or NovoCare.
FDA warning letter to Empower Pharmacy over compounded GLP-1 combinations
FDA posted warning letter 738238, dated September 18, to Empower Pharmacy in Houston. FDA says its tirzepatide-niacinamide and semaglutide-cyanocobalamin products "appear to be essentially copies" of approved drugs and cites sterile products "prepared, packed, or held under insanitary conditions".
What it means if you pay cash: Ask which pharmacy fills your prescription. Programs that rely on add-in formulations may switch pharmacies or change prices.
Novo Nordisk: about 90% of Wegovy pill prescriptions are self-pay
Novo Nordisk's Capital Markets Day presentation says the Wegovy pill has passed 7 million U.S. prescriptions this year, about 90% of them self-pay, and that Novo works with more than nine telehealth companies.
What it means if you pay cash: Brand oral semaglutide is now a mainstream cash-pay option at $149 to $299 a month through NovoCare, worth comparing with compounded injections.
No final FDA decision has been published on the April 30, 2026 proposal (91 FR 23431) to leave tirzepatide, semaglutide and liraglutide off the 503B bulks list; comments closed July 30, 2026 (91 FR 38719). No FDA recalls of compounded GLP-1s were found between September 1 and October 7, 2026. Lilly still plans to file retatrutide in the first quarter of 2027, and no FDA decision on CagriSema had been announced as of October 15, 2026.